Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The MYC insulated genomic domain, also known as an insulated neighborhood, is a discrete structural unit of the genome that encapsulates the MYC proto-oncogene and its associated regulatory elements (Dowen et al., 2014). These domains are formed by DNA loops anchored by the CTCF protein and the cohesin complex, which function to restrict the activity of enhancers to specific target genes within the loop while preventing inappropriate activation by external regulatory elements (Hnisz et al., 2016). In many human cancers, the integrity of the MYC insulated genomic domain is compromised by somatic mutations or deletions that destroy the CTCF-binding boundary sites. This disruption allows neighboring super-enhancers to 'hijack' the MYC promoter, leading to constitutive MYC overexpression and oncogenic transformation (Ji et al., 2016). While the domain itself is a genomic feature rather than a protein, it is a primary focus for therapeutic strategies aimed at disrupting the transcriptional machinery it houses. Current approaches include the use of BET inhibitors like JQ1 to suppress enhancer activity within the domain and CRISPR/Cas9 technologies to repair or restore boundary elements (Schuijers et al., 2018). Understanding the spatial organization of this domain is crucial for developing precision medicines that target the epigenetic drivers of MYC-dependent malignancies.
Inhibition of bromodomain-containing proteins (BET inhibitors) to disrupt super-enhancer activity within the domain; inhibition of transcriptional kinases (CDK7/9) to reduce MYC transcription; CRISPR-mediated restoration of CTCF boundary elements.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MYC insulated genomic domain (MYC IGD).